August 2, 2010 -- In the aftermath of the breakup of the Charles River Labs and WuXi PharmaTech merger, the two companies each reported final reports for their respective 2010 second quarter financial performances. The results? The rejected company, WuXi PharmaTech, increased its guidance for 2010 slightly. Charles River, after deciding WuXi wasn’t worth the money, announced its own revenues declined and trimmed its 2010 outlook. More details....
